Stock Market Live June 12, 2026: S&P 500 (SPY) Green on End of War Hopes

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | Sep 30, 2017 at 8:20 AM EDT

Major Biotech, Pharma and FDA Catalysts Coming in October

24/7 Wall St. has collected several catalysts that are coming up in October for biotech and pharmaceutical companies.

Chris Lange | Sep 29, 2017 at 8:40 AM EDT

Why Zogenix Shares More Than Doubled

Zogenix saw its shares more than double early on Friday after the company reported positive top-line results from its most…

Chris Lange | Sep 28, 2017 at 12:45 PM EDT

AbbVie and Amgen Reach Global Resolution of Humira

AbbVie shares made a handy gain on Thursday after it was announced that the company resolved its Humira patent disputes…

Chris Lange | Sep 28, 2017 at 9:25 AM EDT

Zynerba Pharma Wins Big on Cannabis Trial

Zynerba Pharmaceuticals shares saw a huge gain early on Thursday after the firm announced positive results from its mid-stage cannabinoid…

Chris Lange | Sep 27, 2017 at 10:25 AM EDT

Short Sellers Hike Bets in Major Biotechs

The September 15 short interest data have been compared with the previous report, and short interest in all the selected…

Chris Lange | Sep 27, 2017 at 9:00 AM EDT

Major Pharma Short Interest Piles On

The September 15 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Sep 26, 2017 at 12:10 PM EDT

The List of Failed Alzheimer’s Drug Treatments Keeps Growing

If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech…

Chris Lange | Sep 26, 2017 at 8:50 AM EDT

Why Axovant Is Getting Absolutely Crushed

Axovant Sciences shares cratered early on Tuesday after the firm provided an update from its late-stage Alzheimer’s trial.

Chris Lange | Sep 22, 2017 at 10:45 AM EDT

Is This the Death of Versartis?

Versartis shares absolutely cratered on Friday after the firm announced results from its late-stage Velocity clinical trial of somavaratan in…

Chris Lange | Sep 21, 2017 at 1:20 PM EDT

FDA Crashes Down on Intercept’s Deadly Drug

As we have said before, updates from the FDA have the potential to make or break a company. In this…

Chris Lange | Sep 21, 2017 at 9:55 AM EDT

Can BioCryst Turn Itself Around With This FDA Approval?

BioCryst Pharmaceuticals has received an update from the FDA. This approval is very welcome as BioCryst has been underperforming the…

Chris Lange | Sep 21, 2017 at 8:45 AM EDT

Zai Lab Announces Potential Pricing for IPO

Biopharmaceutical company Zai Lab intends to price its 8 million shares in the range that results in an initial public…

Chris Lange | Sep 20, 2017 at 1:30 PM EDT

Why Alnylam Pharmaceuticals Is Wednesday’s Top Stock

Alnylam Pharmaceuticals saw its shares make a handy gain on Wednesday after the firm gave an update on its late-stage…

John Harrington | Sep 19, 2017 at 1:55 PM EDT

Gallup Poll Finds Rates of Regular Exercise Rising in US Communities

The United States may be among the most obese nations in the world, but there is good news when it…

Chris Lange | Sep 19, 2017 at 11:15 AM EDT

MediWound Secondary Capitalizes on 2017 Success

Biotech companies may attempt a secondary offering after seeing a run in the share price. So now seems the as…

1 … 154 155 156 157 158 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Major Biotech, Pharma and FDA Catalysts Coming in October

Why Zogenix Shares More Than Doubled

AbbVie and Amgen Reach Global Resolution of Humira

Zynerba Pharma Wins Big on Cannabis Trial

Short Sellers Hike Bets in Major Biotechs

Major Pharma Short Interest Piles On

The List of Failed Alzheimer’s Drug Treatments Keeps Growing

Why Axovant Is Getting Absolutely Crushed

Is This the Death of Versartis?

FDA Crashes Down on Intercept’s Deadly Drug

Can BioCryst Turn Itself Around With This FDA Approval?

Zai Lab Announces Potential Pricing for IPO

Why Alnylam Pharmaceuticals Is Wednesday’s Top Stock

Gallup Poll Finds Rates of Regular Exercise Rising in US Communities

MediWound Secondary Capitalizes on 2017 Success

Stock Market Live June 12, 2026: S&P 500 (SPY) Green on End of War Hopes

Live Nasdaq Composite: Markets Hold Breath on Mideast Deal, SpaceX IPO Launch

3 Biggest Oil Giants: Buy, Sell or Hold?

Big Traveler? What Retirement Really Looks Like at 65 With $1.9 Million

He Wants to Spend Retirement Restoring Classic Cars. How Large a Portfolio Does He Need?

Big Traveler? What Retirement Really Looks Like at 65 With $1.9 Million

He Wants to Spend Retirement Restoring Classic Cars. How Large a Portfolio Does He Need?

3 Biggest Oil Giants: Buy, Sell or Hold?

Big Traveler? What Retirement Really Looks Like at 65 With $1.9 Million

Health and Healthcare Articles

All Health and Healthcare Articles

Major Biotech, Pharma and FDA Catalysts Coming in October

Why Zogenix Shares More Than Doubled

AbbVie and Amgen Reach Global Resolution of Humira

Zynerba Pharma Wins Big on Cannabis Trial

Short Sellers Hike Bets in Major Biotechs

Major Pharma Short Interest Piles On

The List of Failed Alzheimer’s Drug Treatments Keeps Growing

Why Axovant Is Getting Absolutely Crushed

Is This the Death of Versartis?

FDA Crashes Down on Intercept’s Deadly Drug

Can BioCryst Turn Itself Around With This FDA Approval?

Zai Lab Announces Potential Pricing for IPO

Why Alnylam Pharmaceuticals Is Wednesday’s Top Stock

Gallup Poll Finds Rates of Regular Exercise Rising in US Communities

MediWound Secondary Capitalizes on 2017 Success

Stock Market Live June 12, 2026: S&P 500 (SPY) Green on End of War Hopes

Live Nasdaq Composite: Markets Hold Breath on Mideast Deal, SpaceX IPO Launch

3 Biggest Oil Giants: Buy, Sell or Hold?

Big Traveler? What Retirement Really Looks Like at 65 With $1.9 Million

He Wants to Spend Retirement Restoring Classic Cars. How Large a Portfolio Does He Need?

Featured Reads

Big Traveler? What Retirement Really Looks Like at 65 With $1.9 Million

He Wants to Spend Retirement Restoring Classic Cars. How Large a Portfolio Does He Need?